Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer

Article Oncology

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le et al.

Summary: Tepotinib demonstrated durable clinical activity in patients with METex14 skipping non-small cell lung cancer and consistent efficacy and manageable safety profile across different subgroups.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Michael A. Vogelbaum et al.

Summary: The purpose of this study is to provide guidelines for clinicians on treating patients with brain metastases from solid tumors. The study conducted a systematic review of the literature and found that surgery is a reasonable option for patients with brain metastases. Local therapy should be given to patients with symptomatic brain metastases, regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless specifically recommended. Several regimens were recommended for different types of cancer. For patients with no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered. Memantine and hippocampal avoidance should be considered for patients receiving whole brain radiation therapy. Patients with low Karnofsky Performance Status and no systemic therapy options do not benefit from radiation therapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami et al.

Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis

Yin Yang et al.

Summary: This study systematically evaluated the efficacy and toxicity of the combination of brain radiotherapy and immune checkpoint inhibitors for non-small-cell lung cancer patients. The results showed that the brain radiotherapy+immune checkpoint inhibitors model had significantly better systemic efficacy than brain radiotherapy alone, with similar neurological adverse events. Concurrent radiotherapy+immune checkpoint inhibitors were identified as the optimal model, achieving the best efficacy without significantly increased adverse events.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Joshua K. Sabari et al.

Summary: Patients with KRAS-mutant NSCLC have a high propensity to develop brain metastases. Adagrasib has shown penetration into the cerebrospinal fluid and demonstrated antitumor activity in multiple preclinical models, supporting its potential clinical activity in the brain for patients with KRASG12C-mutant NSCLC and untreated brain metastases.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Brain Metastases in EGFR- and ALK-Positive NSCLC : Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation

Nicholas J. Thomas et al.

Summary: This study compared outcomes in EGFR- or ALK-positive NSCLC patients who received CNS-penetrant TKI therapy alone versus in combination with radiation, finding no significant differences in disease progression and treatment failure between the two groups.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

Bob T. Li et al.

Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases

Richard S. P. Huang et al.

Summary: This article examines the genomic landscape of NSCLC brain metastases samples with comprehensive genomic profiling. The study found targetable genomic alterations in NSCLC-BM patients, which can inform future clinical studies and suggest the use of brain tissue or cerebral spinal fluid specimens for personalized treatment optimization.

ONCOLOGIST (2022)

添加到收藏夹

Article Critical Care Medicine

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Yosuke Kawashima et al.

Summary: The combination treatment of bevacizumab and erlotinib did not prolong overall survival in patients with metastatic EGFR-mutant NSCLC, but both treatment groups showed relatively long survival durations.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Review Immunology

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Guanqun Yang et al.

Summary: Brain metastases have a negative impact on the prognosis of NSCLC patients. Immune checkpoint inhibitors have been used for the treatment of advanced NSCLC, but their value in patients with brain metastases is unclear. This study reviews the efficacy and adverse effects of ICIs monotherapy, as well as promising combination strategies with chemotherapy, radiotherapy, and anti-angiogenic drugs, and summarizes the methods of patient selection and response assessment.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis

Jonathan T. Yang et al.

Summary: Compared with photon IFRT, proton craniospinal irradiation (pCSI) improved CNS progression-free survival (PFS) and overall survival (OS) for patients with non-small-cell lung cancer and breast cancer with leptomeningeal metastasis (LM), with no increase in serious treatment-related adverse events (TAEs).

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Meeting Abstract Oncology

Genomic profiling and molecular targeting of lung cancer brain metastases

H. Cheng et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Clinical trial of proton craniospinal irradiation for leptomeningeal metastases

T. Jonathan Yang et al.

Summary: Proton craniospinal irradiation is a safe treatment for patients with leptomeningeal metastases from solid tumors, with durable disease control observed in some patients.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy

Lova Sun et al.

Summary: In patients with metastatic non small-cell lung cancer (mNSCLC), the presence of brain metastases (BM) did not significantly impact survival outcomes with pembrolizumab-based therapy. Both systemic and intracranial objective response rates were similar between patients with and without BM. Factors associated with improved survival on Cox analysis included gender, performance status, histology, and first-line therapy.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial

Zhi-qin Lu et al.

Summary: The study revealed that osimertinib combined with bevacizumab is an effective treatment option for patients with LM from EGFRm NSCLC, showing good LM progression-free survival and objective response rate.

THORACIC CANCER (2021)

添加到收藏夹

Article Oncology

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

E. Felip et al.

Summary: The study showed that lorlatinib had clinically meaningful intracranial and extracranial antitumor activity in ALK-positive NSCLC patients who had progressed on second-generation ALK TKIs. The efficacy was particularly notable in patients with fewer lines of therapy, with elevated intracranial ORR compared to extracranial ORR.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Rafal Dziadziuszko et al.

Summary: Entrectinib continues to show a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including those with central nervous system metastases.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

添加到收藏夹

Article Oncology

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely et al.

Summary: Mobocertinib, an oral EGFR inhibitor targeting EGFR gene mutations in non-small cell lung cancer, demonstrated antitumor activity with manageable toxicity in patients with EGFRex20ins mutations in this study, supporting further development in this patient population.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu et al.

Summary: Although the evidence supporting the combination of immune checkpoint inhibitors and antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient, this report presented the efficacy and safety of sintilimab combined with anlotinib in a phase 1b trial. The study showed promising results with a high objective response rate and disease control rate, as well as manageable treatment-related adverse events.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer

Asmat Ullah et al.

Summary: This study investigated the cellular responses to hypoxia and the modulation of APEX1, which regulates HIF-1α and downstream pathways. Hypoxia-induced APEX1/HIF-1α pathways were found to regulate key cellular functions including ROS production, intracellular pH, migration, and angiogenesis. The natural compound Cephalomannine (CPM) exerted inhibitory effects on hypoxic LC cells by inhibiting APEX1/HIF-1α interaction, suggesting it could be a promising compound for lung cancer treatment.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Oncology

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah et al.

Summary: Selpercatinib demonstrates robust and durable intracranial efficacy in patients with RET fusion-positive NSCLC.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park et al.

Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer

Jordi Remon et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407

Steven F. Powell et al.

Summary: This study retrospectively evaluated outcomes in patients with advanced NSCLC and found that first-line pembrolizumab plus chemotherapy was more effective than chemotherapy alone, regardless of baseline brain metastases, improving clinical outcomes and overall survival.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Justin F. Gainor et al.

Summary: The study demonstrated that pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Jarushka Naidoo et al.

Summary: Pembrolizumab showed a 38% CNS response rate in patients with LMM, with a tolerable safety profile and deep responses in selected patients with ICI-responsive tumors. CSF t-DNA may be sensitive for LMM detection, and the immunologic subsets of CNS response require further investigation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Immunotherapy and radiation for high-grade glioma: a narrative review

Kareem R. Fakhoury et al.

Summary: The study investigates the use of immunotherapy in treating HGG, with a focus on how radiation can enhance immunogenicity and the feasibility of combination therapy. While some studies have not shown consistent improvements in clinical outcomes, there are still important lessons to be learned from completed research in this early-stage field.

TRANSLATIONAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001

Paul D. Brown et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

James C. H. Yang et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Florian Klemm et al.

CELL (2020)

添加到收藏夹

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial

Sarah B. Goldberg et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Priscilla K. Brastianos et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Oncology

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Health Care Sciences & Services

Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases

Lu Dai et al.

ANNALS OF PALLIATIVE MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases

T. John et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

Juergen Wolf et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Clinical Neurology

Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors

Lori A. Ramkissoon et al.

FRONTIERS IN NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Central Nervous System Cancers Version 3.2020

Louis Burt Nabors et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Review Oncology

Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data

Eric J. Lehrer et al.

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Mihong Choi et al.

CLINICAL LUNG CANCER (2019)

添加到收藏夹

Article Oncology

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC

Mei-Mei Zheng et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza E. L. Hendriks et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Shirish M. Gadgeel et al.

LUNG CANCER (2019)

添加到收藏夹

Review Oncology

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Adrienne Boire et al.

NEURO-ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study

Birgitte Bjornhart et al.

ACTA ONCOLOGICA (2019)

添加到收藏夹

Meeting Abstract Oncology

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

Alexander E. Drilon et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Alessandro Leonetti et al.

DRUG RESISTANCE UPDATES (2019)

添加到收藏夹

Article Oncology

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial

Alice T. Shaw et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

How we treat patients with leptomeningeal metastases

Emilie Le Rhun et al.

ESMO OPEN (2019)

添加到收藏夹

Review Oncology

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Ferdinandos Skoulidis et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Oncology

Tumour heterogeneity and resistance to cancer therapies

Ibiayi Dagogo-Jack et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y. S. Li et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment

Elie El Rassy et al.

CANCER TREATMENT REVIEWS (2018)

添加到收藏夹

Article Oncology

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

D. Ross Camidge et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients

Arthur Geraud et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Leptomeningeal metastases in non-small-cell lung cancer

Haiying Cheng et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Makoto Nishio et al.

LUNG CANCER (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions

Yifan Wang et al.

FRONTIERS IN PHARMACOLOGY (2018)

添加到收藏夹

Article Oncology

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study

S. Gadgeel et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Yi-Long Wu et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

Thanyanan Reungwetwattana et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin J. Solomon et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC

David R. Spigel et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

William J. Magnuson et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean-Charles Soria et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice T. Shaw et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Respiratory System

Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis

Dianhe Li et al.

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Article Oncology

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Ben-Yuan Jiang et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Oncology

Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era

J. Remon et al.

CANCER TREATMENT REVIEWS (2017)

添加到收藏夹

Review Immunology

The movers and shapers in immune privilege of the CNS

Britta Engelhardt et al.

NATURE IMMUNOLOGY (2017)

添加到收藏夹

Article Oncology

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases

Anna S. Berghoff et al.

ONCOIMMUNOLOGY (2016)

添加到收藏夹

Article Oncology

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

A. S. Mansfield et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large ( > 2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis

Giuseppe Minniti et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)

添加到收藏夹

Article Medicine, General & Internal

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases A Randomized Clinical Trial

Paul D. Brown et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Oncology

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis

Kimberly L. Johung et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

Sai-Hong Ignatius Ou et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yang-Si Li et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib

Justin F. Gainor et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

Paula Mulvenna et al.

LANCET (2016)

添加到收藏夹

Article Oncology

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

David Planchard et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis

Ya-Lan Wu et al.

ONCOLOGY LETTERS (2016)

添加到收藏夹

Article Oncology

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Justin F. Gainor et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer

Isabella Zhang et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James C-H Yang et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

CellSearch® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis

Qian Tu et al.

LUNG CANCER (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor et al.

NATURE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Leticia De Mattos-Arruda et al.

NATURE COMMUNICATIONS (2015)

添加到收藏夹

Review Oncology

Role of Local Radiation Therapy in Cancer Immunotherapy

Sandra Demaria et al.

JAMA ONCOLOGY (2015)

添加到收藏夹

Article Oncology

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Dong-Yeop Shin et al.

JOURNAL OF THORACIC ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study

Masaaki Yamamoto et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases

A. Ali et al.

CURRENT ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer

Andrew J. Weickhardt et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Yuhui Huang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

添加到收藏夹

Review Oncology

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

Agnes V. Tallet et al.

RADIATION ONCOLOGY (2012)

添加到收藏夹

Article Oncology

RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF BEVACIZUMAB THERAPY FOR RADIATION NECROSIS OF THE CENTRAL NERVOUS SYSTEM

Victor A. Levin et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

添加到收藏夹

Article Oncology

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

Eric L. Chang et al.

LANCET ONCOLOGY (2009)

添加到收藏夹

Article Oncology

The biology of metastasis to a sanctuary site

Diane Palmieri et al.

CLINICAL CANCER RESEARCH (2007)

添加到收藏夹

Article Oncology

Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system

JS Barnholtz-Sloan et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

添加到收藏夹

Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer

相关参考文献

导出引文

分享论文